CONKO-006:吉西他滨联合索拉非尼或安慰剂用于胰腺癌R1切除术后辅助治疗的随机双盲IIb期研究最终结果
CONKO-006研究纳入122例胰腺导管腺癌R1切除术后患者,随机接受吉西他滨+索拉非尼或吉西他滨+安慰剂治疗12个周期。结果显示两组无复发生存期(中位8.5 vs 9.4个月,p=0.730)和总生存期(中位17.6 vs 17.5个月,p=0.481)均无显著差异。探索性分析提示术后化疗超过6个周期的患者总生存期显著延长(p=0.021)。
要点
- 吉西他滨联合索拉非尼未改善R1切除术后胰腺癌的无复发生存期和总生存期。
- 联合索拉非尼组腹泻和GGT升高发生率较高,但整体安全性可控。
- 术后化疗超过6个周期可能与总生存期延长相关,值得进一步研究。
核心结论
- 在胰腺癌R1切除术后患者中,吉西他滨联合索拉非尼对比吉西他滨联合安慰剂未改善无复发生存期或总生存期。
研究设计与样本
- 随机、双盲、安慰剂对照、多中心IIb期研究,计划检测18个月无复发生存率从42%提高至60%。
- 2008年2月至2013年9月共纳入122例胰腺导管腺癌R1切除术后患者,57例随机至吉西他滨+索拉非尼组,65例至吉西他滨+安慰剂组。
- 两组患者特征均衡:中位年龄63/63岁,T3/T4比例97%/97%,淋巴结阳性率86%/85%。
主要发现
- 截至2017年8月,118例(97%)患者发生无复发生存事件。
- 无复发生存期中位吉西他滨+索拉非尼组8.5个月 vs 吉西他滨+安慰剂组9.4个月,p=0.730。
- 总生存期中位吉西他滨+索拉非尼组17.6个月 vs 吉西他滨+安慰剂组17.5个月,p=0.481。
- 3/4级毒性:腹泻(12% vs 2%)、GGT升高(19% vs 9%)、乏力(5% vs 2%)、高血压(5% vs 2%)、中性粒细胞减少(18% vs 25%)、血小板减少(9% vs 2%)。
- Landmark分析提示接受超过6个周期术后化疗的患者总生存期显著更长(p=0.021)。
临床怎么用
- 不推荐在胰腺癌R1切除术后辅助治疗中常规联合索拉非尼。
- 术后化疗超过6个月可能使R1切除患者生存获益,但需进一步研究验证。
局限性
- 本研究为IIb期研究,样本量有限(122例),统计效能可能不足以检测微小差异。
- Landmark分析为探索性,术后化疗超过6个周期的生存获益需前瞻性研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: CONKO-006 was designed for patients with pancreatic adenocarcinoma with postsurgical R1 residual status to evaluate the efficacy and safety of the combination of gemcitabine and sorafenib (GemSorafenib) compared with those of gemcitabine + placebo (GemP) for 12 cycles. PATIENTS AND METHODS: This randomised, double-blind, placebo-controlled, multicenter study was planned to detect an improvement in recurrence-free survival (RFS) from 42% to 60% after 18 months. Secondary objectives were overall survival (OS), safety and duration of treatment. RESULTS: 122 patients were included between 02/2008 and 09/2013; 57 were randomised to GemSorafenib and 65 to GemP. Patient characteristics were wellbalanced (GemSorafenib/GemP) in terms of median age (63/63 years), tumour size (T3/T4: 97/97%), and nodal positivity (86/85%). Grade 3/4 toxicities comprised diarrhoea (GemSorafenib: 12%; GemP: 2%), elevated gamma-glutamyl transferase (GGT) (19%; 9%), fatigue (5%; 2%) and hypertension (5%; 2%), as well as neutropenia (18%; 25%) and thrombocytopenia (9%; 2%). By August 2017, 118 (97%) RFS event had occurred. There were no difference in RFS (median GemSorafenib: 8.5 versus GemP: 9.4 months; p = 0.730) nor OS (median GemSorafenib: 17.6 versus GemP: 17.5 months; p = 0.481). Landmark analyses suggest that patients who received more than six cycles of postoperative chemotherapy had significantly longer OS (p = 0.021). CONCLUSION: CONKO-006 is the first randomised clinical trial to include exclusively patients with PDAC with postsurgical R1 status thus far. Sorafenib added to gemcitabine did neither improve RFS nor OS. However, postoperative treatment exceeding six months seemed to prolong survival and should be further investigated in these high-risk patients. CLINICAL TRIAL INFORMATION: German Tumor Study Registry (Deutsches Krebsstudienregister), DRKS00000242.
引用
- Sinn M, Liersch T, Riess H, et al. CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results. Eur J Cancer. 2020. PMID: 32890813. doi:10.1016/j.ejca.2020.06.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。